Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 14/20 | 0.37 |
| ▸ | DRD3 | P35462 | 14/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8020258 | 0.91 | GHSR (0.39) | HSD11B1DRD2DRD3 | |
| SCHEMBL989840 | 0.82 | DRD1 (0.37) | HSD11B1DRD2 | |
| SCHEMBL989087 | 0.79 | HSD11B1 (0.38) | HSD11B1DRD2DRD3HRH3 | |
| SCHEMBL989686 | 0.79 | CNR2 (0.35) | HSD11B1DRD2DRD3HRH3DRD4 | |
| SCHEMBL1862538 | 0.76 | SLC6A9 (0.47) | — | |
| SCHEMBL7529635 | 0.75 | ACHE (0.35) | HRH3MTNR1AMTNR1B | |
| SCHEMBL8027935 | 0.74 | ESR2 (0.42) | — | |
| SCHEMBL7474566 | 0.73 | SIGMAR1 (0.44) | DRD2DRD3DRD4 | |
| SCHEMBL8027135 | 0.72 | GHSR (0.40) | — | |
| SCHEMBL8033549 | 0.72 | DRD2 (0.39) | HSD11B1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957089-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-17 | — | — | US | disclosed |
| US-8653100-B2 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130203749-A1 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2271625-B1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | HSD11B1 1303/4885DRD2 2992/4885DRD3 2959/4885 |
| US-20130203749-A1 | Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy | GOLT1B, SLC10A1, SUGT1 | HSD11B1 1303/4885DRD2 2992/4885DRD3 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.